

Contents

1. Introduction.....	4
Approach to disclosure at AZ.....	4
2. Definitions	5
2.1. Recipients	5
2.1.1. Definition of an HCP.....	5
2.1.2. Definition of an HCO	5
2.2. Kind of ToVs	5
2.2.1. Donations and Grants	6
2.2.2. Sponsorship agreements	6
2.2.3. Registration fees	6
2.2.4. Travel and Accommodation.....	7
2.2.5. Fees for service and consultancy and related expenses	7
2.2.6. Research and Development.....	7
3. Scope of disclosure	8
3.1. Products concerned	8
3.2. Excluded ToVs.....	8
3.2.1. Hospitality costs	8
3.2.2. Informational and Educational Materials and Items of Medical Utility .	8
3.2.3. Logistical costs.....	9
3.2.4. Donations to charitable organisations & Patient Organisations	9
3.3. Date of ToVs	9
3.4. Direct ToVs	9
3.5. Indirect ToVs.....	9
3.5.1. Indirect ToVs through CROs	9
3.5.2. Indirect ToVs through other third parties	10
3.5.3. Indirect ToVs through HCOs	10
3.6. ToVs in case of partial attendances or cancellation.....	10
3.7. Cross-border activities	10
3.7.1. Cross-border activities	10
4. Specific considerations	11
4.1. Country unique identifier	11
4.2. Self-incorporated HCP	11
5. Consent management	11
5.1. Consent collection.....	11
5.1.1. HCO consent	11

5.1.2.	HCP consent.....	11
5.2.	Management of recipient consent withdrawal.....	12
5.3.	Management of recipient's requests.....	12
5.4.	Partial consent	12
6.	Disclosure form	12
6.1.	Disclosure platform	12
6.1.1.	Date of publication	12
6.1.2.	Retention of data.....	12
6.2.	Disclosure language.....	12
6.3.	Pre-disclosure	12
7.	Disclosure financial data.....	13
7.1.	Currency	13
7.2.	Value Added Tax (VAT) and other taxes	13

1. Introduction

Approach to disclosure at AZ

Collaborative working between medical professionals and healthcare organisations has long been a positive driver for advancements in patient care and the development of innovative medicine. Medical professionals and the organisations with whom they work provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and disease management experience. Furthermore, as the primary point of contact with patients, the medical professional can offer invaluable expert knowledge on patient outcomes and therapy management. This helps to adapt our products to better suit patients and thereby improve patient care overall.

Healthcare professionals and organisations should be fairly compensated for the services they provide to pharmaceutical companies. The EFPIA Disclosure Code provides accuracy and transparency in disclosing the scope and value of such collaborative work, and it will become an important step towards building greater trust between the pharmaceutical industry, medical community and patients.

As a member company of KEFEA and as a full corporate member of EFPIA, AstraZeneca (“AZ”) is committed to transparency around interactions with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) and that these are captured and reported in line with all applicable local transparency requirements.

The aims of the EFPIA Disclosure Code and its local interpretation in the KEFEA Code of Conduct– to promote ethical and transparent interactions with the Healthcare community – are fully aligned with AZ’s own policies. Interactions with HCP/HCOs are governed by the AZ Ethical Interactions (EI) Policy and supporting Standards, including zero tolerance for giving or receiving anything of value that is intended or could be seen as improper influence.

Producing transparency reporting is an opportunity for AZ to demonstrate its commitment to the values and principles behind the EFPIA Disclosure Code and other transparency requirements in Europe.

The objective of this note is to explain AZ’s approach to disclosure, to include key definitions, the scope of disclosed activities and key elements of the process followed to capture and report data.

At a high level, there are three main tenets that characterize the AZ approach:

(1) Affiliate accountability and regional consolidation

Affiliates are responsible for capturing the Transfers of Value (ToVs) made in their affiliates and for validating the accuracy of the data. A regional reporting solution consolidates the ToVs, providing consistency and automating inclusion of cross border payments within Europe. Other cross border payments are collected through a payment system (US) or manually (rest of world).

(2) Compliance with local codes

Unless there are strong legal mandatory requirements, affiliates have transposed the Code in full i.e. without deviations. In each country, AZ will comply with applicable local disclosure requirements. There may be variations (stricter than the provision in the Code) or deviations (where because of mandatory national regulations the code cannot be transposed in full).

(3) One disclosure per market, including all ToVs paid directly through entities belonging to AZ or indirectly through third parties acting on behalf of AZ

The entity included in reporting for Cyprus is:
Alector Pharmaceuticals Ltd

For Cyprus, disclosure is made on KEFEA's website (<http://kefea.org.cy>) through a link that directs users to Alector's website.

2. Definitions

2.1. Recipients

2.1.1. Definition of an HCP

The definition of an HCP in Cyprus is:

Any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Europe. For the avoidance of doubt, the definition of HCP includes: (i) any official or employee of a government agency or other organisation (whether in the public or private sector) that may prescribe, purchase, supply or administer medicinal products and (ii) any employee of a Member Company whose primary occupation is that of a practising HCP, but excludes all other employees of a Member Company and a wholesaler or distributor of medicinal products.

2.1.2. Definition of an HCO

The definition of an HCO in Cyprus is:

Any legal person (i) that is a healthcare, medical or scientific association or organisation (irrespective of the legal or organisational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organisations within the scope of the PO Code) or (ii) through which one or more HCPs provide services.

2.2. Kind of ToVs

2.2.1. Donations and Grants

AZ provides support to medical or scientific education, advances in medical or scientific research, health or healthcare systems or disaster relief through financial or non-financial ToVs to legitimate, established organisations.

AZ can provide this support through:

- Contributions or Sponsorships (or referred to as Grants) to support initiatives in HCP Education, including education about healthcare systems and practices, Medical or Scientific Research, or Partnerships.
- Donations to a non-profit or public sector healthcare organisation (HCO) intended to support their charitable mission and activities. Donations and Grants to Patient Organisations or as part of Community Investments to charities and other non-profit non-HCOs are subject to separate disclosure and thus excluded.

Donations to HCOs can be both monetary and donations in kind. Product Donations subject to the applicable law are given in circumstances of national emergency, international or national disaster relief or other genuine public health need. AZ charitable product donations and processes are aligned to the World Health Organisation (WHO) Guidelines for Drug Donations.

2.2.2. Sponsorship agreements

AZ gives contributions, through financial or non-financial support to legitimate, established organisations for medical or scientific education of external stakeholders, organizing or hosting educational or scientific events (including independent congresses). These contributions aim to increase the scientific or educational quality of the event and/or support with logistics in modest venues or with incidental hospitality, in line with AZ's own ethical principles. The mandatory Sponsorship Agreements will describe the purpose of the sponsorship and for what the funds are to be used.

Sponsorship packages may also include satellite symposia and the sponsoring of speakers or faculty.

ToVs are made to either the HCO directly or to an event organizer or other third party appointed by the HCO to manage the event. In all cases, ToVs are disclosed against the HCO that ultimately benefits.

Where contributions made to HCOs include support for travel & accommodation for HCPs to attend Independent Congresses and the HCPs benefitting from this support are unknown, this payment will be assigned to the EFPIA category "Sponsorship Agreements".

2.2.3. Registration fees

As part of support to continuous medical education, AZ provides support to HCOs or HCPs to cover the costs of registration fees for HCPs to attend selected independent congresses and where provided to HCOs, also for other educational/scientific events.

Where these are provided to HCOs, AZ is not involved in the selection of the HCPs.

Where these are provided to individual HCPs, the purpose of the support is to enable delegates (max two per year):

- to attend presentations or participate in scientific exchange on significant developments related to AZ products or uses or related to AZ's scientific research; or,
- to support the performance of a contract.

All arrangements are generally paid directly to travel and or /accommodation providers or organiser.

2.2.4. Travel and Accommodation

As part of support to continuous medical education, AZ provides support to HCOs or HCPs to cover the costs for Travel and Accommodation for HCPs to attend selected independent congresses and/or AZ Organised Meetings and where provided to HCOs for other educational/scientific events.

These costs can include costs of flights, trains, hotel accommodation, taxis, bus transfers, and other travel costs.

Costs for ground transportation (e.g. bus or taxi) that are organised for group transportation and not assigned to certain HCPs are reported in aggregate, but where the identity of the HCPs is known, these are split by HCP.

2.2.5. Fees for service and consultancy and related expenses

AZ engages an HCP/HCO for services when there is a genuine and legitimate business need and where the HCP/HCO is qualified and appropriate to provide the services. These services are paid with a Fee for Service at Fair Market Value.

These services can include:

- Speaking at and chairing meetings
- Training services
- Participation at advisory board meetings
- Medical writing
- Data analysis
- Development of education materials
- General consulting/advising
- Services performed in connection with a third party congress

As part of the written Fee for Services Agreement, related expenses can be paid for and can include costs of flights, trains, car hire, tolls, parking fees, taxis, bus transfers and hotel accommodation. All costs are paid by AZ to travel and or /accommodation providers or meeting organizers (where relevant).

2.2.6. Research and Development

All ToVs related to the planning or conduct of non-clinical studies, clinical trials and non-interventional studies performed by AZ or by Clinical Research Organisations

on AZ's behalf that are prospective in nature are considered Research & Development ToVs and are reported on an aggregate basis.

ToVs related to R&D activities can include the following:

- Science Units are separate entities within AZ and perform non-clinical studies (as defined in OECD Principles on Good Laboratory Practice) and clinical trials (as defined in Directive 2001/20/EC). Where Science Units have made ToVs to HCPs or HCOs, these have been considered to be related to R&D activities. Events or consultancy fees in relation to R&D are also reported in the aggregate.
- Costs related to events that are clearly related to activities covered by the R&D ToV (e.g. clinical investigator meetings, Steering Committee meetings for a specific clinical trial)

Retrospective non-interventional studies or other studies that are not submitted to authorities as per local drug law do not fall under the category of R&D activities. The ToVs related to those studies will be reported as Fee for Service under name of the individual recipient.

3. Scope of disclosure

3.1. Products concerned

AZ is a science focused company, developing innovative medicines that are prescription only medicines and interactions with HCPs/HCOs are focused on the development and promotion of prescription medicines. Consequently, only ToVs relating to prescription medicines are being disclosed.

3.2. Excluded ToVs

3.2.1. Hospitality costs

As per Section 1.02 of the Disclosure Code, hospitality costs are not disclosable if in line with the limits set within the national association following Art 10 of the HCP Code. AZ applies these limits for AZ Organised & Sponsored Meetings, and therefore costs of meals & drinks are excluded. However, where meals and drinks make up an integral and inseparable part of contributions to the cost of events or sponsoring as part of Sponsorship Agreements with HCOs, they have been included in Contributions to Cost of Events.

3.2.2. Informational and Educational Materials and Items of Medical Utility

As per Section 1.02 of the EFPIA Disclosure Code, items of medical utility for HCPs and informational and educational material are not disclosed where in line with Art 9 of the HCP Code which states that "The transmission of informational or educational materials is permitted provided it is: (i) "inexpensive"; (ii) directly relevant to the practice of medicine or pharmacy; and (iii) directly beneficial to the care of patients."

3.2.3. Logistical costs

Logistical costs related to AZ Organised Meetings (e.g. room hire, technicians, personnel) are excluded. However, ToVs to participants, such as support for travel and accommodation or speaker fees to HCPs are included in the relevant cost category.

3.2.4. Donations to charitable organisations & Patient Organisations

All ToVs to non-HCO organisations are out of scope and excluded e.g. charitable organisations.

All ToVs to Patient Organisations are out of scope as separate reporting requirements provide transparency on ToVs to these organisations. These requirements are outlined in the EFPIA Code of Practice on Relationships between the Pharmaceutical Industry and Patient Organisations.

3.3. Date of ToVs

Where the ToV is a payment, values are reported on the date of the payment i.e. the date the funds are transferred to the recipient's bank account. Payments made in 2015 for activities related to 2014 are included. If consent to disclose these has been obtained, they are reported against the individual. If not, they will be reported in aggregate.

Where ToVs relate to multi-year contracts, only the ToVs made in the reporting year are included.

Where the ToV is a benefit in kind, values are reported on the date the recipient received the benefit.

3.4. Direct ToVs

The natural or legal person that holds the bank account on which the money is transferred is considered the recipient of the ToV and will be disclosed.

Direct ToVs are captured in SAP based on their vendor code, General Ledger code and activity code. They are then mapped to the appropriate EFPIA disclosure activity category for reporting.

3.5. Indirect ToVs

3.5.1. Indirect ToVs through CROs

Where a Clinical Research Organisation acts on behalf of AZ to make ToVs to HCPs/HCOs, these are within the scope of the Disclosure and are reported at an

aggregate level under R&D as long as their activities fall within the scope of the definition of R&D activities.

3.5.2. Indirect ToVs through other third parties

Where third parties are appointed by an HCO to manage an event, and where the HCO ultimately benefits from that ToV, these ToVs are disclosed against the HCO. Where an event is organised on behalf of multiple HCOs without clarity on allocation, the value is divided equally between the HCOs.

Where third parties are appointed by AZ to make travel and accommodation arrangements for HCPs who are providing services or are supported to attend events, these ToVs are disclosed against the HCP.

Any additional administration fees charged by agencies are not included, as these are not ToVs to HCPs or HCOs.

3.5.3. Indirect ToVs through HCOs

Where ToVs are made to an individual HCP indirectly via an HCO and where AZ has obtained the consent, these will be disclosed against the HCP in line with local association guidelines.

3.6. ToVs in case of partial attendances or cancellation

Where an HCP/HCO does not receive the benefit due to a no show or a cancellation of event, the associated costs are not reported, such as the cost of cancelling a hotel booking or accommodation. In case of partial attendance, only the benefits actually received are reported.

Where AZ has to pay cancellation fees to HCP/HCOs as per service contracts, due to cancellation of initiatives or events, these payments are reported.

3.7. Cross-border activities

3.7.1. Cross-border activities

AZ makes their best efforts to capture and report all ToVs to HCPs and HCOs with their primary practice in a country with EFPIA Disclosure Code and/or other cross border transparency reporting requirements and has introduced a group wide reporting requirement for that purpose. The country of disclosure will be determined by the address of principal practice for HCPs and the address of registration for an HCO.

Disclosures are made locally, either on each affiliate's website, or on a separate disclosure platform if prescribed by the national code or law.

4. Specific considerations

4.1. Country unique identifier

The registration number of the HCP to his/her respective body (ie Pancyprian Medical Association, Pharmacy Association etc) is the unique identifier for any HCP and used to ensure that transactions are reported against the correct recipient.

The Vendor Code is 1 unique identifier for any HCO, generated by Alector Pharmaceuticals Ltd and used to ensure that transactions are reported against the correct recipient.

4.2. Self-incorporated HCP

Where a self-employed HCP is incorporated in a legal entity that consists of only that 1 HCP, this is considered as an HCO, as it is a legal entity but remains subject to providing consent, as per data privacy recommendations.

If an HCP is "self-employed" but has not set up a legal entity, they are treated as an individual HCP.

5. Consent management

5.1. Consent collection

5.1.1. HCO consent

In Cyprus HCOs are reported without the need for a consent since these are legal entities and therefore any information relating to them does not classify as personal data.

5.1.2. HCP consent

All efforts have been made at local level to achieve a high level of individual HCP payment disclosure whilst recognising applicable Data Privacy regulations.

A consent clause is included in every engagement contract. This requires continuous tracking of HCP's consent status and updating of the consent flag. The last consent or reject will be considered the final one and all the payments to the HCP will be disclosed individually (if consent is given in the last contract) or reported in aggregate (if consent is not given in the last contract).

HCPs' data are reported only after consent is given. If no response is received, a "no" response is assumed and the data are reported in aggregate.

5.2. Management of recipient consent withdrawal

Consent to disclose can be withdrawn at any time before and after public disclosure.

- If consent is withdrawn before disclosure the consent value is changed to "No"
- After data is published on the KEFEA website, consent withdrawal follows the process defined by KEFEA.

5.3. Management of recipient's requests

Requests or disputes are managed at a local level. HCPs or HCOs should contact/email their local day-to-day contact if they believe any data reported is inaccurate.

Alector Pharmaceuticals Ltd commits to resolving disputes and republishing if required within 30 days of receiving notification of the dispute.

5.4. Partial consent

If consent is requested per engagement and the HCP provides partial consent, the final response (yes or no) will be applied to all transactions for that reporting year.

6. Disclosure form

6.1. Disclosure platform

6.1.1. Date of publication

The date of publication for Cyprus is June 20th – June 30th 2016 in line with EFPIA requirements.

6.1.2. Retention of data

Alector Pharmaceuticals Ltd maintains relevant records of the disclosures for a minimum of 5 years.

6.2. Disclosure language

Disclosure is made in English.

6.3. Pre-disclosure

A process allows HCPs and HCOs to review ToVs planned to be published prior to disclosure on the KEFEA's website.

7. Disclosure financial data

7.1. Currency

Disclosure will be made in Euro.

7.2. Value Added Tax (VAT) and other taxes

VAT and withholding taxes are excluded.